MSI2 and breast cancer: Collectively, these results highlighted the clinical relevance of LIN28/MSI2-mediated YAP1 regulation in BC patients, and targeting of YAP/TEAD-mediated transcriptional output may represent a treatment strategy for LIN28/MSI2-overexpressing BCs.